Kathleen Moore, MD, MS

Kathleen N. Moore, MD, MS, is an associate director of clinical research at the Stephenson Cancer Center, the director of the Oklahoma TSET Phase I Program, and a professor in the Section of Gynecologic Oncology at Oklahoma University (OU) College of Medicine, OU Health.

Articles

Looking Ahead: The Evolving Role of ADCs in Gynecologic Malignancies

June 20th 2025

Panelists discuss how the evolving role of antibody-drug conjugates (ADCs) in treating gynecologic cancers, including ovarian, endometrial, and cervical cancers, offers exciting opportunities for more personalized treatments that could improve progression-free survival and quality of life, while addressing challenges in therapy sequencing, toxicity management, and biomarker-driven approaches.

Mirvetuximab Soravtansine in Practice: Expert Approaches to Adverse Event Management in Ovarian Cancer

June 20th 2025

Panelists discuss how early detection and proactive management of ocular toxicities associated with mirvetuximab soravtansine, including regular screening, eye exams, and collaboration with ophthalmologists, are essential for ensuring timely intervention and minimizing long-term complications such as cataracts, particularly as the drug transitions to broader clinical use.

Navigating T-DXd-Related Toxicity: Mitigation and Management Strategies in Gynecological Cancer

June 20th 2025

Panelists discuss how managing interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine requires proactive monitoring, including baseline and ongoing chest CT scans, early intervention with steroids, and close collaboration with pulmonologists and radiologists to minimize risks and ensure patient safety during treatment.

Exploring Emerging ADCs and Their Potential Impact in Gynecologic Cancers

June 13th 2025

Panelists discuss how the rapid evolution of antibody-drug conjugates (ADCs) in gynecologic cancers, including promising agents such as mirvetuximab soravtansine and toriluzumab, is generating excitement, with a focus on optimizing treatment sequencing and exploring combinations of ADCs to improve outcomes for patients with platinum-resistant ovarian cancer.

Navigating Treatment Sequencing Decisions in the Ovarian Cancer Paradigm

June 13th 2025

Panelists discuss how mirvetuximab soravtansine (MIRV), an antibody-drug conjugate, has become a vital treatment for platinum-resistant ovarian cancer, highlighting its effectiveness in patients with high folate receptor alpha expression, its well-tolerated profile with manageable toxicities, and the potential for expanding its use into earlier treatment lines and combination therapies.

Efficacy, Tolerability, and Quality of Life with ADCs in Gynecological Malignancies

June 6th 2025

Panelists discuss how the accelerated approval of trastuzumab deruxtecan (T-DXd) offers a promising new treatment option for patients with HER2-positive gynecologic cancers, while highlighting the need for confirmatory trials to refine patient selection, testing methodologies, and treatment sequencing strategies, as well as managing varying patient responses and addressing tolerability concerns.

Integrating T-DXd in HER2+  Gynecologic Cancers: Impact on Treatment Decisions and Sequencing

June 6th 2025

Panelists discuss how the recent accelerated approval of trastuzumab deruxtecan (T-DXd) in HER2-expressing endometrial cancer prompts critical questions about treatment sequencing, as clinicians weigh efficacy, toxicity, and emerging evidence to personalize therapy in a rapidly evolving gynecologic oncology landscape.

Expert Perspectives: Standardizing HER2 Testing in Gynecological Cancer

May 30th 2025

Panelists discuss how evolving insights into HER2 expression—drawn from parallels with breast cancer—highlight the need for standardized HER2 testing in gynecologic oncology, as emerging data on HER2-low status and variability in current testing approaches underscore both the therapeutic potential of antibody-drug conjugates (ADCs) and the challenges of implementing precision medicine in this setting.

Molecular Testing in Ovarian and Endometrial Cancer: Evolving Approaches and Best Practices

May 30th 2025

Panelists discuss how antibody-drug conjugates (ADCs) and molecular testing are reshaping treatment strategies in ovarian and endometrial cancers by enabling more personalized, targeted care, while addressing practical challenges such as tissue limitations, tumor heterogeneity, and the evolving role of liquid biopsy in optimizing diagnostic accuracy.

Dr Moore on Key 2024 Updates in FRα+ Ovarian Cancer Management

November 27th 2024

Dr Moore on Ongoing ADC Development in Ovarian Cancer

November 27th 2024

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates under investigation in ovarian cancer.

Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer

November 4th 2024

Kathleen N. Moore, MD, MS, discusses the evolving landscape in managing platinum-resistant ovarian cancer.

Dr Moore on Continued Efforts to Utilize Immunotherapy in Ovarian Cancer

November 21st 2023

Kathleen N. Moore, MD, MS, discusses continued efforts to target the immune system in ovarian cancer through the use of immunotherapy, as well as alternative strategies being explored in this tumor type.

Dr Moore on the Design of a Phase 1/2 Study of Ubamatamab in Ovarian Cancer

September 6th 2023

Kathleen N. Moore, MD, MS, discusses the design of the ongoing, first-in-human, phase 1/2 study of the MUC16- and CD3-targeted bispecific antibody ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr Moore on Investigating Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

July 29th 2023

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Unmet Needs and Clinical Pearls for Metastatic Endometrial Cancer

November 1st 2022

Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.

Dr. Moore on the Investigation of Nab-sirolimus in TSC1/2-Mutated Gynecologic Cancers and Other Solid Tumors

October 27th 2022

Kathleen N. Moore, MD, MS, discusses the investigation of nab-sirolimus in TSC1/2-mutated gynecologic cancers.

Emerging Biomarkers and Drug Targets in mEC

October 25th 2022

Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.

Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting

October 25th 2022

Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.

Considerations for Second-Line and Higher Treatment of Recurrent mEC

October 18th 2022

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.